Kobo O, Cavender MA, Jensen TJ, Kuhlman AB, et al. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis. Diabetes Obes Metab 2023 Dec 11. doi: 10.1111/dom.15396.
PMID: 38082468